Talk:Assessment of the health impacts of H1N1 vaccination/Group C

From Testiwiki
< Talk:Assessment of the health impacts of H1N1 vaccination
Revision as of 13:51, 4 April 2011 by Jpmannikko (talk | contribs) (Pandemrix should not be used because of narcolepsy risk)
Jump to: navigation, search

Pandemrix should not be used because of narcolepsy risk

Jukka-Pekka?, Kati?

How to read discussions

Statements: Pandemrix should not be used any more anywhere because its narcolepsy risk is too high. NOTE! The time of the statement is September 2010.

Resolution: Resolution not yet found.

(A stable resolution, when found, should be updated to the main page.)

Argumentation:

1 : Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST)

2 : The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST)

3 : In Finland, THL decided to stop the use of Pandemrix. --Jouni 23:05, 31 March 2011 (EEST), [1]

4 : There have been claims that THL would have had a conflict of interest, as it had received financing worth EUR 6 million from the vaccine producer GalaxoSmithKline (GSK) --Jpmannikko 16:51, 4 April 2011 (EEST)

5 : The World Health Organization (WHO) examined the link between THL and GSK and found no evidence that research funding and the pharmaceutical company would have influenced the choise of vaccines --Jpmannikko 16:51, 4 April 2011 (EEST)